Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
IMTX
#6996
Immatics N.V. Ordinary Shares
10.340
0
+4.23%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+4.23%
Monatliche Änderung
+3.19%
6 month change
-0.10%
Jahresänderung
-0.10%
Vorheriger Schlusskurs
9.920
0
Open
10.340
0
Bid
Ask
Low
10.340
0
High
10.340
0
Volumen
18
Märkte
Aktien
Gesundheitswesen
IMTX
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
121.55 M
345.81 M
Valuation ratios
Enterprise value
864.22 M
3.27 B
Price to earnings ratio
—
—
Price to sales ratio
—
—
Price to cash flow ratio
—
—
Price to book ratio
—
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
—
—
Return on equity %
—
—
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
—
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
—
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
—
—
Net current asset value per share
—
—
Tangible book value per share
—
—
Working capital per share
—
—
Book value per share
—
—
Nachrichten
Immatics Stock: PRAME Leader’s Transition To Commercial Reality (NASDAQ:IMTX)
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Salesforce and Micron Tech among market cap stock movers on Friday
Micron, Salesforce among market cap stock movers on Friday
Leerink Partners erhöht Kursziel für Immatics auf 17 US-Dollar
Immatics stock price target raised to $17 from $16 at Leerink Partners
Iovance Biotherapeutics: Several Positives, But Competition Still Threatens (NASDAQ:IOVA)
Company News for Nov 18, 2025
Guggenheim hebt Kursziel für Immatics nach positiven TCR-Pipeline-Daten auf 19 US-Dollar an
Guggenheim raises Immatics stock price target to $19 on positive TCR pipeline data
Immatics NV: EPS verfehlt Schätzungen um 0,04 € - Umsatz schlechter als erwartet
Immatics NV earnings missed by €0.04, revenue fell short of estimates